Adlai Nortye vs Apollomics
ANL and APLM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ANL | APLM |
|---|---|---|
| Size and price | ||
| Share price | $10.61 | $17.68 |
| Change, 1 year | 559% | 7.0% |
| Beta (5Y) | 1.67 | 0.68 |
| Employees | – | 14 |
| StockData Score | ||
| Total score | 0 | 0 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 0 | 0 |
| Dividend score | 0 | 0 |
| Profitability | ||
| Operating margin | −714% | – |
| Net margin | −711% | – |
| FCF margin | −673% | – |
| Financial health | ||
| Interest coverage | −23.3× | – |
| Current ratio | 0.65 | 0.96 (better) |
| Piotroski F-score | 1 | – |
| Ownership | ||
| Held by institutions | 22.1% | – |
| Held by insiders | 14.7% | 76.0% |
| Insider net buying, 12 months | −$411K | $8.3M (better) |
Go deeper
- ANL stock overview
- ANL income statement
- ANL valuation and score
- APLM stock overview
- APLM income statement
- APLM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.